Global Healthcare Conference in London

17-20 November 2025 | The Waldorf Hilton
#JefferiesHealthcare

At our 2025 conference, Jefferies welcomed our partners and over 800 leading global public and private companies across the biotechnology, pharmaceuticals, medical technology, and healthcare services sectors.

icon-handshake

This year’s gathering marked the sixteenth anniversary of Europe’s largest healthcare-dedicated conference, reinforcing its position as a premier conference for industry leaders.

icon-meeting

The conference addressed near and long-term investment opportunities and examined the trends shaping healthcare in the U.S. and globally, providing actionable insights for companies and investors.

2025 Conference Highlights

By the numbers

800+

Healthcare Companies

4,100

Attendees

9,500

Institutional Investor Meetings

15,000+

Total Meetings

Thank You to Our 2025 Sponsors

  • Healthcare
    September 2025
    $2,000,000,000
    Sale to Lotus Pharmaceutical
    Joint Financial Advisor
  • Healthcare
    April 2025
    Undisclosed
    Sale to KKR
    Joint Financial Advisor
  • Healthcare
    July 2025
    Undisclosed
    Majority Sale to EQT
    Sole Financial Advisor
  • Healthcare
    July 2025
    Undisclosed
    Investment by Bain Capital, Kohlberg and Mubadala Investment Company
    Lead Financial Advisor
  • Healthcare
    December 2024
    Undisclosed
    Acquisition of Synthon
    Joint Financial Advisor
  • Healthcare
    August 2025
    $750,000,000
    Convertible notes offering
    Joint Bookrunner
  • Healthcare
    March 2025
    $2,200,000,000
    Sale to and Subsequent Merger with Advanced Instruments
    Sole Financial Advisor
  • Healthcare
    September 2025
    $8,000,000,000
    Sale to Genmab
    Sole Financial Advisor
  • Healthcare
    August 2025
    Undisclosed
    Sale to CapVest
    Joint Lead Financial Advisor
  • Healthcare
    June 2025
    $9,500,000,000
    Sale to Sanofi
    Lead Financial Advisor
  • Healthcare
    January 2025
    $14,630,000,000
    Sale to Johnson & Johnson
    Joint Financial Advisor
  • Healthcare
    November 2025
    $259,000,000
    Common Stock Offering
    Lead Left Bookrunner
  • Healthcare
    October 2025
    $316,000,000
    Common Stock Offering
    Lead Left Bookrunner
  • Healthcare
    October 2025
    $288,000,000
    Common Stock Offering
    Lead Left Bookrunner
  • Healthcare
    October 2025
    $150,000,000
    Common Stock Offering
    Lead Left Bookrunner
  • Healthcare
    October 2025
    $120,000,000
    Private Placement of Equity
    Lead Placement Agent
  • Healthcare
    September 2025
    $288,000,000
    Common Stock Offering
    Lead Left Bookrunner
  • Healthcare
    September 2025
    $144,000,000
    Convertible Notes Offering
    Lead Left Bookrunner
  • Healthcare
    June 2025
    $230,000,000
    Common Stock Offering
    Lead Left Bookrunner
  • Healthcare
    June 2025
    $230,000,000
    Common Stock Offering
    Joint Bookrunner
  • Healthcare
    June 2025
    $345,000,000
    Common Stock Offering
    Lead Left Bookrunner
  • Healthcare
    April 2025
    $300,000,000
    PIPE in support of reverse merger with Aerovate Therapeutics
    Lead Placement Agent
  • Healthcare
    March 2025
    $500,000,000
    Common Stock Offering
    Joint Bookrunner
  • Healthcare
    January 2025
    $403,000,000
    Common Stock Offering
    Joint Bookrunner
  • Healthcare
    December 2024
    $250,000,000
    Private Placement of Equity
    Lead Placement Agent
  • Healthcare
    October 2025
    €808,000,000
    Initial Public Offering
    Joint Bookrunner
  • Healthcare
    January 2025
    Undisclosed
    Acquisition of Medical Media Business from FUJIFILM Irvine Scientific
    Sole Financial Advisor
  • Healthcare
    January 2025
    Undisclosed
    Investment from TA Associates and Novo Holdings
    Sole Financial Advisor
  • Healthcare
    April 2025
    Undisclosed
    Sale of stake to Hellman & Friedman
    Joint Financial Advisor
  • Healthcare
    March 2025
    €250,000,000
    Preferred Equity Investment from Carlyle
    Sole Financial Advisor
  • Healthcare
    February 2025
    €404,000,000
    Initial Public Offering
    Joint Global Coordinator and
    Joint Bookrunner